A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Bioretec Files for CE Mark for its Bioresorbable RemeOs Magnesium Screw in the EU

Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has submitted an application for the CE mark for the first product in its new RemeOs™ product family, the RemeOs™ trauma screw.

The CE mark is a legal prerequisite in order to commercialize a medical device in the European Union. Bioretec’s target is to receive the CE mark and to introduce the bioresorbable magnesium alloy trauma screw into the markets in the European Union during 2022.

RemeOs™ bioresorbable magnesium implant helps bone to heal and is naturally replaced by bone, eliminating the need for removal operations that are in many cases required when using traditional implants. In the CE mark filing, the intended use of RemeOs™ trauma screw is for the fixation of bone fractures (osteosynthesis) and for the fixation after osteotomies e.g., the correction of deformities or malalignments.

“Filing for the CE mark on schedule is an important milestone in the commercialization of our first RemeOs™ product and a great end to our first year as a listed company. I am proud of our team’s commitment and effort to reach this milestone. It follows our strategic goal of developing and commercializing innovations that increase patients’ quality of life,” says Timo Lehtonen, CEO of Bioretec.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy